RxDoctor Payments Data

Shovek Boyadjian

Family Medicine · Panorama City, CANPI 1619950342

Payments from drug & device makers

$11,885in general payments, 2019–2025

Across 516 payments — averaging $23.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AstraZeneca$1K
  • AbbVie$1K
  • Novo Nordisk$843
  • Novartis$804
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$595
  • plus $6K from 41 others

What the payments were for

  • Food & beverage$11,863100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,885 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$658,257
Medicare patients
795
Services billed
8,388

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase140$315,354
LinzessLinaclotide461$250,157
JardianceEmpagliflozin356$211,842
OzempicSemaglutide213$201,024
EliquisApixaban482$182,826
TrulicityDulaglutide170$161,461
JanuviaSitagliptin Phosphate327$161,337
Repatha SureclickEvolocumab263$146,969
Metformin Er GastricMetformin Hcl152$145,194
MounjaroTirzepatide130$136,451
EntrestoSacubitril/Valsartan227$123,812
Trelegy ElliptaFluticasone/Umeclidin/Vilanter185$117,290
Tresiba Flextouch U-200Insulin Degludec184$109,269
TrintellixVortioxetine Hydrobromide229$107,445
ProliaDenosumab62$104,729

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Namzaric, Restasis$1,159$631,391724 claims
Lilly USA, LLCTrulicity, Mounjaro$401$297,913300 claims
Boehringer IngelheimJardiance, Tradjenta$531$263,233497 claims
Novo NordiskOzempic, Rybelsus$843$262,938280 claims
MerckJanuvia, Janumet$147$208,087419 claims
PfizerEliquis$97$182,826482 claims
NovartisEntresto$804$123,812227 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,443$119,180202 claims
GSKTrelegy Ellipta$530$117,290185 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$419$107,445229 claims
AmgenProlia$1,507$104,72962 claims
Astellas Pharma US IncMyrbetriq$78$81,663180 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Panorama City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →